Preliminary Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-46 (canceled)

Claim 47 (previously presented): A non-vesicular preparation comprising at least one cationic amphiphile in a concentration of about 10 mM to about 600 mM with a mean chain length from C12 to C24, optionally at least one further amphiphile of up to about 60 mol % based on the total amphiphile concentration and optionally at least one stabilizing agent in a concentration of about 10 mM to about 600 mM in an aqueous phase, wherein said preparation is transparent, isotropic and substantially homogeneous.

Claim 48 (previously presented): The preparation of claim 47, comprising at least one cationic amphiphile in a concentration of about 25 mM to about 500 mM.

Claim 49 (previously presented): The preparation of claim 47, comprising a stabilizing agent in a concentration of about 100 mM to about 500 mM.

Claim 50 (previously presented): The preparation of claim 47, wherein said cationic amphiphile is lipid with net positive charge, lysolipid with net positive charge, or pegylated lipid with a net positive charge.

Claim 51 (previously presented): The preparation of claim 50, wherein said cationic amphiphile is cationic lipid with at least one tertiary amino or quaternary ammonium group.

Claim 52 (previously presented): The preparation of claim 51, wherein said tertiary amino ammonium group is N-[1-(2,3-diacyloxy)propyl]-N,N-dimethylamine.

Claim 53 (previously presented): The preparation of claim 51, wherein quaternary ammonium group is N-[1-(2,3-diacyloxy)propyl]-N,N,N-trimethyl ammonium.

Claim 54 (previously presented): The preparation of claim 47, wherein said further amphiphile has a net negative or a net neutral charge.

Claim 55 (previously presented): The preparation of claim 47, wherein said further amphiphile is sterol or lipid.

Claim 56 (previously presented): The preparation of claim 55, wherein the sterol is cholesterol.

Claim 57 (previously presented): The preparation of claim 55, wherein said lipid is phospholipid, lysolipid, lysophospholipid, sphingolipid or pegylated lipid with a net negative or neutral charge.

Claim 58 (previously presented): The preparation of claim 57, wherein the phospholipid is diacylphosphatidylcholine.

Claim 59 (previously presented): The preparation of claim 47, wherein said stabilizing agent is a sugar, an alcohol or a combination thereof.

Claim 60 (previously presented): The preparation of claim 47, wherein said stabilizing agent is trehalose, maltose, sucrose, glucose, lactose, dextran, mannitol or sorbitol.

Claim 61 (previously presented): The preparation of claim 47, further comprising an active compound.

Claim 62 (previously presented): The preparation of claim 61, wherein said active compound may be hydrophilic, hydrophobic or amphipathic.

Claim 63 (previously presented): The preparation of claim 62, wherein said compound is a therapeutic agent.

Claim 64 (previously presented): The preparation of claim 63, wherein said therapeutic agent is camptothecin or a derivative thereof, a microtubuli interacting agent, a vinca alkaloid, a platinum complex, an anthracycline, or a statin.

Claim 65 (previously presented): The preparation of claim 64, wherein said therapeutic agent is a derivative of camptothecin in its carboxylate form.

Claim 66 (previously presented): The preparation of claim 64, wherein said microtubuli interacting agent is a taxane, epothilone, discodermolide, laulimalide, isolaulimalide, eleutherobin, colchicine, or a derivative thereof.

Claim 67 (previously presented): The preparation of claim 63, wherein said therapeutic agent is in the range of about 0.1 mol % to about 20 mol %-based on total amphiphile concentration.

Claim 68 (previously presented): The preparation of claim 61, wherein said compound is a diagnostic agent.

Claim 69 (previously presented): The preparation of claim 68, wherein said diagnostic agent is in the range of about 0.1 mol % to about 50 mol %-based on total amphiphile concentration.

Claim 70 (previously presented): A method of producing a liposome suspension comprising using a preparation of claim 47 to form a liposome suspension.

Claim 71 (previously presented): A method of producing a liposome suspension comprising diluting the preparation of claim 47 with an aqueous solution.

Claim 72 (previously presented): A pharmaceutical composition comprising the preparation of claim 47, optionally together with a pharmaceutically acceptable carrier, diluent and/or adjuvant.

Claim 73 (previously presented): A method of preparing a medicament or a diagnostic formulation comprising using a preparation of claim 72 to produce a medicament or diagnostic formulation.

Claim 74 (previously presented): A method of preparing a medicament or a diagnostic formulation comprising using a preparation of claim 47 to produce a medicament or diagnostic formulation.

Claim 75 (previously presented): A method of treating angiogenesis associated condition comprising administering a pharmaceutical composition of claim 72.

Claim 76 (previously presented): A method of treating angiogenesis associated condition comprising administering a liposome suspension produced by the method of claim 71.

Claim 77 (previously presented): A method of claim 75, wherein said angiogenesis associated condition is cancer, chronic or acute inflammatory diseases, rheumatoid arthritis, dermatitis, psoriasis or wound healing.

Claim 78 (previously presented): A method of producing the non-vesicular preparation of claim 47, comprising:

(a) providing

i) said cationic amphiphile, optionally said further amphiphile, optionally said stabilizing agent, optionally said active compound, and

ii) an aqueous phase; and

(b) dispersing the components of i) in said aqueous phase of ii).

Claim 79 (previously presented): The method of claim 78, wherein step (b) comprises a single phase evaporation or high pressure homogenization method.

Claim 80 (previously presented): The method of claim 78, comprising:

(a) providing

i) said cationic amphiphile, optionally said further amphiphile, optionally said stabilizing agent, and

ii) an aqueous solution;

(b) dispersing the components of i) in said aqueous phase of ii); and

(c) adding an active agent to the dispersion of step (b).

Claim 81 (previously presented): The method of claim 80, wherein step (b) comprises a single phase evaporation or high pressure homogenization method.

Claim 82 (previously presented): A method of producing the non-vesicular preparation of claim 47, comprising:

a) providing said cationic amphiphile, optionally said further amphiphile, optionally said stabilizing agent, optionally said active compound and an aqueous phase; and

b) subjecting the components of step a) to conditions so that an isotropic, transparent and substantially homogenous preparation is formed.

Claim 83 (previously presented): A method of claim 82, wherein step b) comprises a single phase evaporation or high pressure homogenization method.